EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts

Frank Buttgereit, Andrea Everding, Ioana Andreica, Herbert L Kellner, Florian Schuch, Cornelia Weyand, Paul M Stewart, Peter A Merkel, Christian Dejaco, Frank S Czerwiec, Ketan Desai, David A Katz

Annals of the Rheumatic Diseases · 2026-05 · 85 (5) · 921-931

DOI: 10.1016/j.ard.2025.10.015 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-05. Verfasst von Frank Buttgereit und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Prednisolone, Polymyalgia Rheumatica, Glucocorticoids, 11-beta-Hydroxysteroid Dehydrogenase Type 1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Glucocorticoids effectively treat many diseases, but toxicity limits their utility. We aimed to learn whether, by reducing active intracellular glucocorticoid exposures, the 11β-hydroxysteroid dehydrogenase type 1 inhibitor clofutriben could selectively reduce glucocorticoid efficacy but reduce toxicity more strongly. We hypothesised that by increasing the prednisolone dose, it might be possible to restore efficacy back to the original level, thereby improving the benefit-risk profile. METHODS: In sequential cohorts, adults with polymyalgia rheumatica received (single blind) prednisolone 10 mg/d with placebo for 2 weeks, then clofutriben with either prednisolone 10, 15, 20, or 30 mg/d for 2 weeks. RESULTS: Forty-nine and 47 participants completed each trial period with evaluable data. Five who received prednisolone 10 mg/d with clofutriben experienced clinical relapse. No clinical relapses occurred during other treatments. Participants reported more severe symptoms and physical disability when prednisolone 10 mg/d or 15 mg/d, but not 20 mg/d or 30 mg/d, was given with clofutriben. Inflammatory biomarkers followed a similar pattern. Across all prednisolone doses, clofutriben coadministration mitigated glucocorticoid-related adverse effects on biomarkers of bone turnover, lipid metabolism, hypercoagulability, and cardiovascular and adrenal function. CONCLUSIONS: Further trials to assess clofutriben's potential to improve the benefit-risk profile of prednisolone are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrednisolonePolymyalgia RheumaticaGlucocorticoids11-beta-Hydroxysteroid Dehydrogenase Type 1HumansFemaleAgedMaleSingle-Blind MethodMiddle AgedTreatment OutcomeDrug Therapy, CombinationDose-Response Relationship, DrugAged, 80 and over

Substanzen

PrednisoloneGlucocorticoids11-beta-Hydroxysteroid Dehydrogenase Type 1

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Hamburger Rheuma Forschungszentrum II, Hamburg, Germany.
  • Ruhr-Universität Bochum, Bochum, Germany; Rheumazentrum Ruhrgebiet, Herne, Germany.
  • Schwerpunktpraxis für Rheumatologie und Gastroenterologie München, München, Germany.
  • Internistische Praxisgemeinschaft Rheumatologie Nephrologie Erlangen, Erlangen, Germany.
  • Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Buttgereit, F., Everding, A., Andreica, I., Kellner, H. L., Schuch, F., Weyand, C., Stewart, P. M., Merkel, P. A., Dejaco, C., Czerwiec, F. S., Desai, K., & Katz, D. A. (2026). Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Annals of the Rheumatic Diseases, 85(5), 921-931. https://doi.org/10.1016/j.ard.2025.10.015

Vancouver

Buttgereit F, Everding A, Andreica I, Kellner HL, Schuch F, Weyand C, et al. Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts. Annals of the Rheumatic Diseases. 2026;85(5):921-931. doi:10.1016/j.ard.2025.10.015

BibTeX
@article{Buttgereit2026,
  author = {Buttgereit, Frank and Everding, Andrea and Andreica, Ioana and Kellner, Herbert L and Schuch, Florian and Weyand, Cornelia and Stewart, Paul M and Merkel, Peter A and Dejaco, Christian and Czerwiec, Frank S and Desai, Ketan and Katz, David A},
  title = {Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {5},
  pages = {921--931},
  doi = {10.1016/j.ard.2025.10.015}
}
Kostenlos starten →